



OPEN
ENTREPRENEURSHIP

CO-FOUNDER NEEDED

Apply to co-found no later than 16 November 2025
<https://open-entrepreneurship.com/cofounder/>

We leverage dextran nanoparticles to expand high-quality, potent CAR T cells, aiming to broaden the scope of CAR T therapy and enhance its efficacy

NANODEX BIO

THE PROBLEM

[Suboptimal CAR T cell phenotype leads to tumor relapse remains a substantial challenge (30% - 60%)]

OUR SOLUTION

Using unique dextran nanopatform (T-Expand) to produce the next-generation CAR-T cells featuring a superior phenotype, stronger tumor-cell killing, and durable persistence for sustained therapeutic benefit

PATENT STATUS

Patent has been filed: PCT/European Patent Application No. 241 789 57.7

FINANCIAL OVERVIEW

[We are not selling kits; our focus is to develop and commercialize next-generation CAR T cell therapies expanded with dextran nanoparticles, generating revenue directly from therapeutic sales and strategic partnerships]

MILESTONES ACHIEVED

[Preclinical validation] → demonstrate superior CAR T phenotype & efficacy

IND-enabling studies → complete tox & CMC package

Phase I trial → establish safety and early efficacy

Phase II trial → demonstrate efficacy in target indications, seek partnerships

Phase III / commercialization → pivotal data, regulatory approval, market launch

TARGET MARKET & CUSTOMERS

Primary Market: Oncology patients eligible for CAR T therapies, initially hematologic malignancies and expanding into solid tumors.

Customers: Hospitals, cancer centers, and biopharma partners adopting or co-developing next-generation CAR T treatments.

CO-FOUNDER PROFILE WE ARE LOOKING FOR

Must-have qualifications/background

1. Proven experience in biotech/biopharma business development or commercialization
2. Track record in fundraising, investor relations, or venture creation
3. Strong understanding of regulatory and clinical development pathways for advanced therapies
4. Ability to build strategic partnerships with pharma, biotech, and clinical centers

Nice-to-have qualifications/background

1. MBA or equivalent experience in life sciences entrepreneurship
2. Prior involvement in cell/gene therapy ventures or CAR T commercialization
3. Network within oncology, immunotherapy, or biotech VC ecosystems
4. Experience with licensing deals, joint ventures, or M&A in healthcare

Personal fit

1. Entrepreneurial mindset, comfortable with high-risk/high-reward environment
2. Transparent communicator and collaborative decision-maker
3. Values scientific excellence and patient impact as core drivers

TASKS & RESPONSIBILITIES (FIRST 3 MONTHS)

1. Shape the business strategy and go-to-market model
2. Lead investor outreach and fundraising preparation (deck, financial model, networking)
3. Support IP strategy and regulatory planning
4. Build relationships with potential pharma/biotech partners
5. Set up the company structure (legal, governance, early operations)

ACADEMIC & ENTREPRENEURIAL BACKGROUND OF CURRENT CO-FOUNDERS


Tao Zheng – Postdoctoral researcher; PhD in nanomedicine, expertise in nanoparticle design, and translational oncology. Inventor on two key patents.

[Yi Sun] – Professor, specialist in nanobiotechnology, co-inventor of patents, PI of collaborative grants.

[Sine Reker Hadrup] – Professor, specialist in nanotechnology & Cancer Immunotherapy, 10 patents, 3 spinouts, 1 exit

PHYSICAL ADDRESS

DTU healthtech



ABOUT OPEN ENTREPRENEURSHIP

Open Entrepreneurship is a collaboration between all Danish universities aiming to create more research-based startups.

www.open-entrepreneurship.com



SUPPORTED BY

Uddannelses- og
Forskningsministeriet